{"id":"W4293678347","doi":"10.1016/j.jstrokecerebrovasdis.2022.106742","title":"Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention","year":2022,"lang":"en","type":"article","venue":"Journal of Stroke and Cerebrovascular Diseases","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Hospital Edmonton; University of Alberta Hospital; Population Health Research Institute; McMaster University","funders":"Janssen Research and Development; Deutsches Zentrum für Neurodegenerative Erkrankungen; Daiichi Sankyo Europe; Sanofi; Deutsches Zentrum für Herz-Kreislaufforschung; Kowa Company; Ionis Pharmaceuticals; Alexion Pharmaceuticals; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Bristol-Myers Squibb; AstraZeneca; Novo Nordisk; American Heart Association","keywords":"Medicine; Clopidogrel; Stroke (engine); Aspirin; Clinical endpoint; Internal medicine; Randomized controlled trial; Placebo; Physical therapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04279477,0.003548637,0.005070613,0.001315408,0.001667095,0.00300972,0.002876455,0.00473558,0.01206922],"category_scores_gemma":[0.03394368,0.001961929,0.00304112,0.001183545,0.003499968,0.002347317,0.001378367,0.005950437,0.004334135],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001378669,"about_ca_system_score_gemma":0.007087883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005391596,"about_ca_topic_score_gemma":0.001237596,"domain_scores_codex":[0.9766641,0.01738441,0.001381967,0.001913838,0.001725656,0.0009299975],"domain_scores_gemma":[0.9917203,0.003293925,0.001444998,0.0009840189,0.001214887,0.00134187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.8289427,0.007186441,0.004422963,0.02249578,0.004096457,0.0006470403,0.0007042598,0.002529019,0.004687721,0.02145604,0.0234815,0.07935014],"study_design_scores_gemma":[0.9042376,0.03311267,0.003123404,0.003396459,0.00296279,0.0002078084,0.0001157624,0.002933101,0.00140248,0.01024973,0.03811574,0.0001424502],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.02777553,0.01189025,0.01964979,0.007727465,0.004997439,0.9142888,0.003825413,0.0003891317,0.009456149],"genre_scores_gemma":[0.08043845,0.00318674,0.03338125,0.006996823,0.001311767,0.8710682,0.001121091,0.00004939925,0.002446258],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.04279477,"threshold_uncertainty_score":0.2263231,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0243804379774977,"score_gpt":0.2831299040048981,"score_spread":0.2587494660274004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}